Advertisement
Home2024-01-11T09:26:42-05:00

Top Story

  • Health Policy
    February 23rd, 2024

    Colorado’s prescription drug affordability board is considering capping the cost of Amgen’s autoimmune medication Enbrel, marking a potential first in state-led efforts to tackle high drug prices. The board, criticized for its slow action in reducing drug costs, found Enbrel’s annual price of over $46,000 per [...]

HEOR

RWE

Advertisement

Featured Webinars

Handpicked Promotions & Highlights

Latest in Catalyst News powered by BioPharmCatalyst

02/23/2024 04:46 PM ET

Biodexa Pharmaceuticals plc BDRX date announcement

Biodexa Pharmaceuticals plc already had four catalyst announcements coming up, but they added another one today. Now that the Phase 1 trial of MTX110 - (PNOC015) is completed, Biodexa Pharmaceuticals plc will announce their top-line [...]

Read More
02/23/2024 04:46 PM ET

Regeneron Pharmaceuticals REGN date announcement

Regeneron Pharmaceuticals now has 18 catalyst announcements on the calendar after revealing the date on which they will release trial results for Dupixent (dupilumab) - (NOTUS). Now that the PDUFA priority review trial is completed, [...]

Read More
02/23/2024 04:46 PM ET

Brainstorm Cell Therapeutics BCLI date announcement

Brainstorm Cell Therapeutics will be announcing top-line results for their recent BLA Filing trial for NurOwn on February 29, 2024. The community is currently slightly bullish on the prospects of progression, as the bulls outnumber [...]

Read More
02/23/2024 04:46 PM ET

BioMarin Pharmaceutical BMRN earnings announcement

BioMarin Pharmaceutical exceeded their EPS estimate and fell in line with their revenue estimate, according to their recent quarterly earnings data. EPS was estimated to be $0.23 and the actual figure came [...]

Read More

Latest From Our Blog

Receive essential insights, resources and content direct to your inbox

Hit subscribe to stay informed!

Go to Top